China's COVID-19 vaccine production capacity may cover 40% of population by mid-2021 - disease control head

Yu did not disclose when the 3 billion dose capacity would be hit. Production capacity of a single-dose vaccine from CanSino Biologics could reach an annual 500 million doses this year, a scientist leading research for the shot told state media in February.


Reuters | Beijing | Updated: 05-03-2021 19:17 IST | Created: 05-03-2021 19:17 IST
China's COVID-19 vaccine production capacity may cover 40% of population by mid-2021 - disease control head
  • Country:
  • China

China's production capacity of COVID-19 vaccines could be sufficient to supply enough doses for 40% of the population by mid-2021, the country's head of disease control authorities said on Friday. The country's production capacity may also be large enough to allow 70%-80% of its 1.4 billion population to be vaccinated by the beginning of 2022, Gao Fu, director of the Chinese Center for Disease Control and Prevention, told reporters on the sidelines of the annual meeting of the government's top advisory body.

"The possibility exists," Gao said, but cautioned that translating production capacity into actual products that meet necessary standard was "a complicated process". He added that the estimate was his personal view as a scientist rather than an official forecast.

More than 52 million doses were administered in China as of end-February, which equates to fewer than 4 doses per 100 people, a ratio much lower than the level seen in countries such as Israel and United States. China, which has approved four locally developed vaccines for general public use, has not disclosed how many doses it is actually making.

Sinovac Biotech said early this week its production capacity of the firm's two-dose vaccine CoronaVac could hit 2 billion doses by June. A Wuhan-based unit of China National Pharmaceutical Group (Sinopharm) is running a facility that can churn out as many as 100 million doses of its vaccine a year, while a Beijing-based subsidiary of Sinopharm has an annual capacity of 1 billion doses of a separate product. Both Sinopharm units' vaccines require two doses.

Sinopharm could expand COVID-19 vaccine production capacity to 3 billion doses per year, said Yu Qingming, chairman of Sinopharm Group, another unit of Sinopharm which is not directly involved in COVID-19 vaccine production, according to state media. Yu did not disclose when the 3 billion dose capacity would be hit.

Production capacity of a single-dose vaccine from CanSino Biologics could reach an annual 500 million doses this year, a scientist leading research for the shot told state media in February.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback